Medical options are driven primarily by our own research emanating from the DRIz as well as from our international collaborators through the Pacific Pediatric Neuro-Oncology Consortium ( as well as the Childhood Brain Tumour Tissue Consortium (

We are focused on optimizing combinations of drugs and treatments in optimized sequences as well as CNS directed delivery supported by our focus on developing improved therapeutic options for children with DIPG and other malignant midline gliomas.

We strive to collaborate and partner with academic institutions, foundations, pharmaceutical companies and device manufacturers that can help to support and provide us with the best tools and knowledge to improve efficacy for these deadly tumours.

Add comment